Skip to main contentAI and Advanced
/
FISCHER · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
FI
NSE · Equity shares · Chemical Manufacturing-0.42 · -1.23%
Fischer Medical Ventures FISCHER
NSE:INR 33.6
BSE:INR 33.2
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for FISCHER
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 34.02
Day rangeINR 32.96 — INR 34.71
52-week rangeINR 31.05 — INR 124.7
Volume3.66 L
Market cap2,558.55
P/E100.43
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)308.58
Net Income (INR Cr)31.02
Rev Growth (5 Year %)351.21
EPS Growth (5 Year %)-11.26
P/E Ratio100.43
Book Value5.79
EPS0.45
Price/BV5.80Computed
Research path: Interpret Fischer Medical Ventures's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
FISCHERFischer Medical Ventures1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 671.01 | 457.37 | 86.32 |
| Cash Equivalents | 11.89 | Not available | 0.95 |
| Other Liabilities Total | 0.99 | 0.09 | Not available |
| Long Term Debt | 0.26 | 0.26 | 0 |
| Common Stock Total | 65.45 | 63.8 | 53.5 |
| Other Equity Total | 1.47 | -0.22 | Not available |
| Other Current Assets Total | 84.49 | 0.4 | 2.06 |
| Total Assets | 671.01 | 457.37 | 86.32 |
| Current Portof LT Debt/Capital Leases | 8.12 | 8.03 | 0.43 |
| Total Equity | 384.39 | 337.52 | 81.11 |
| Long Term Investments | 168.66 | 10.77 | 1.21 |
| Retained Earnings(Accumulated Deficit) | 317.47 | 33.13 | 27.61 |
| Total Common Shares Outstanding | 65.45 | 63.8 | 53.5 |
| Tangible Book Valueper Share Common Eq | 5.79 | 5.21 | 1.47 |
| Goodwill Net | 5.28 | 5.28 | 2.22 |
| Total Liabilities | 286.63 | 119.85 | 5.21 |
| Total Debt | 107.08 | 85.37 | 1.68 |
| Short Term Investments | 19.66 | 147.09 | 40.05 |
| Cashand Short Term Investments | 31.55 | 251.36 | 41 |
| Total Receivables Net | 288.89 | 104.16 | 22.87 |
| Notes Payable/Short Term Debt | 72.1 | 60.14 | 0 |
| Deferred Income Tax | 0 | 0.39 | 0.12 |
| Accounts Receivable-Trade Net | 288.8 | 76.18 | 22.87 |
| Property/Plant/Equipment Total-Net | 29.33 | 19.72 | 12.49 |
| Minority Interest | 0.76 | 0.34 | Not available |
| Total Current Liabilities | 258.03 | 101.82 | 3.83 |
| Total Inventory | 12.66 | 9.16 | 4.48 |
| Accounts Payable | 102.6 | 20.65 | 2.16 |
| Other Currentliabilities Total | 75.2 | 12.71 | 1.25 |
| Total Long Term Debt | 26.86 | 17.21 | 1.25 |
| Other Long Term Assets Total | 50.16 | 17.73 | 0 |
| Total Current Assets | 417.59 | 365.29 | 70.41 |
| Capital Lease Obligations | 26.59 | 16.94 | 1.25 |
| Accumulated Depreciation Total | Not available | -2.84 | Not available |
| Accrued Expenses | Not available | 0.29 | Not available |
| Prepaid Expenses | Not available | 0.21 | Not available |
| Additional Paid-In Capital | Not available | 240.82 | Not available |
| Cash | Not available | 104.26 | Not available |
| Property/Plant/Equipment Total-Gross | Not available | 21.44 | Not available |
| Note Receivable-Long Term | Not available | 38.59 | Not available |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %240.82
Margins
Operating Margin 12m12.96
Operating Margin 5y Avg10.13
Net Profit Margin 12m10.05
Net Profit Margin 5y7.67
Yield
Dividend Yield %0.13
Valuation
Price to Sale Ratio8.29
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk47.3
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Asian Paints | INR 2,675 | 2.57 L | 58.09 | — |
| Solar Industries India | INR 18,870 | 1.71 L | 99.61 | — |
| Pidilite Industries | INR 1,578.45 | 1.61 L | 64.76 | — |
| SRF | INR 2,851.45 | 84,764.8 | 44.57 | — |
| Linde India | INR 6,897.25 | 58,822.66 | 110.53 | — |
Shareholding
Ownership
- Promoter
- 62.15%
- FII
- 5.48%
- Other
- 32.37%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Fischer Medical Ventures Appoints Tay Chin Kwang as Group Director of Finance to Strengthen Healthcare and Life Sciences Growth - businessnewsthisweek.comMarket news · 21 Jul 2026, 1:02 pm
Fischer Medical Ventures Appoints Tay Chin Kwang as Group Director of Finance to Strengthen Healthcare and Life Sciences Growth businessnewsthisweek.com
Fischer Medical Ventures introduces Vecura in India to advance AI-enabled molecular research - BioSpectrum IndiaMarket news · 17 Jul 2026, 5:26 am
Fischer Medical Ventures introduces Vecura in India to advance AI-enabled molecular research BioSpectrum India
Fischer Medical Ventures brings AI-enabled molecular research platform Vecura to India - Express PharmaMarket news · 16 Jul 2026, 1:56 pm
Fischer Medical Ventures brings AI-enabled molecular research platform Vecura to India Express Pharma
Fischer Medical Ventures expands AI partnership to accelerate drug discovery in India - Indian Pharma PostMarket news · 16 Jul 2026, 1:09 pm
Fischer Medical Ventures expands AI partnership to accelerate drug discovery in India Indian Pharma Post
Fischer Medical Ventures Ltd. Share Price Live Today - CNBC TV18Market news · 14 Jul 2026, 3:46 pm
Fischer Medical Ventures Ltd. Share Price Live Today CNBC TV18
Fischer Medical strengthens AI-led drug discovery push through Nanyang Biologics partnership - Indian Pharma PostMarket news · 12 Jul 2026, 6:30 pm
Fischer Medical strengthens AI-led drug discovery push through Nanyang Biologics partnership Indian Pharma Post
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsTo consider other business matters
- annual General MeetingPOM
- annual General MeetingAGM
- dividendRs.0.0050 per share(0.5%)Final Dividend
- splitsStock split from Rs. 10/- to Re. 1/-.
Rusaka Markets Community
Discussion and sentiment for Fischer Medical Ventures
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Fischer Medical Ventures Limited is an India-based company. The Company specializes in trading and manufacturing of magnetic resonance imaging (MRI) systems. It is engaged in the development of advanced medical diagnostic and imaging technologies, through its wholly owned subsidiary, Time Medical International Ventures (India) Private Limited. It comprises a manufacturing facility that can produce 160 MRI machines per year. It provides a comprehensive range of healthcare solutions across various specialties, namely Ophthalmology, Cardiology, Oncology, Dentistry, Neurology, Mental Health, and Point of Care. The Company's products include PICA, MONA, EMMA, NEONA, and NOVA.
Company facts
- Industry
- Chemical Manufacturing
- Sector
- Chemical Manufacturing
- NSE Code
- FISCHER
- BSE Code
- 524743
Questions
Stock FAQ
What is the symbol and ISIN of Fischer Medical Ventures?
Fischer Medical Ventures has the symbol FISCHER and ISIN - INE771F01041.
What is the current price of Fischer Medical Ventures?
Fischer Medical Ventures is currently trading at INR 33.60.
What are the year high and year low of Fischer Medical Ventures?
Fischer Medical Ventures has a year high of INR 124.70 and a year low of INR 31.05.
What is the market capitalization of Fischer Medical Ventures?
Fischer Medical Ventures has a market capitalization of INR 2,558.55 crore.
What is the P/E ratio of Fischer Medical Ventures?
Fischer Medical Ventures has a P/E ratio of 100.43.
What is the dividend yield of Fischer Medical Ventures?
Fischer Medical Ventures has a dividend yield of 0.13%.
How is the financial performance of Fischer Medical Ventures based on revenue, net income, and EPS?
Fischer Medical Ventures has revenue of INR 308.58 crore, net income of INR 31.02 crore, and EPS of INR 0.40.
What is the book value of Fischer Medical Ventures?
Fischer Medical Ventures has a book value of INR 5.79.
What is the debt-to-equity ratio of Fischer Medical Ventures?
Fischer Medical Ventures has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Fischer Medical Ventures?
Fischer Medical Ventures has a price-to-book ratio of 5.80 and a price-to-sales ratio of 8.29.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.